USFDA approves Novartis' heart failure drug
USFDA has given its nod to the combination drug, Entresto made by Novartis to treat heart failure. This approval comes being based on studies having more than 8000 people showing that the drug reduced rates of heart-related death and hospitalization compared with older drugs.
Clyde Yancy, chief of cardiology at Chicago’s Northwestern Memorial Hospital, said that Entresto is “one of the few times that we have identified a medication that is better than the standard. It’s clearly superior to what we have.”
Dr. Yancy, a heart-failure specialist, is independent of the drug maker, Novartis. He estimated that of the six million people in the U.S. with heart failure, “at least half may be candidates” for the medicine. And he said that the drug “may fundamentally change their lives for the better.”
Heart failure is a condition in which the patient’s heart has lost some of its pumping capacity, and it can degenerate into a situation where patients have difficulty breathing and end up in the emergency room.
Clyde Yancy, chief of cardiology at Chicago’s Northwestern Memorial Hospital, said that Entresto is “one of the few times that we have identified a medication that is better than the standard. It’s clearly superior to what we have.”
Dr. Yancy, a heart-failure specialist, is independent of the drug maker, Novartis. He estimated that of the six million people in the U.S. with heart failure, “at least half may be candidates” for the medicine. And he said that the drug “may fundamentally change their lives for the better.”
Heart failure is a condition in which the patient’s heart has lost some of its pumping capacity, and it can degenerate into a situation where patients have difficulty breathing and end up in the emergency room.
Next Story
